← Back to Clinical Trials
Recruiting NCT07035171

NCT07035171 CABGpreHAB - a Feasibility Study Protocol

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07035171
Status Recruiting
Phase
Sponsor Rigshospitalet, Denmark
Condition Ischaemic Heart Disease
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2025-06-24
Primary Completion 2026-06-18

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Multimodal prehabilitation interventionControl (Standard treatment)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2025-06-24 with a primary completion date of 2026-06-18.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Patients with ischemic heart disease (IHD) awaiting coronary artery bypass graft (CABG) surgery often face challenges like advanced age, frailty, comorbidities, and physical inactivity. These factors, combined with the physiological and psychological stress of surgery, can hinder postoperative recovery. Traditionally, strategies to improve surgical outcomes focus on the intra- and postoperative periods. However, the pre-surgery waiting period offers a "window of opportunity" for prehabilitation, which aims to enhance patients' functional capacity through exercise, nutrition, and psychological support. The CABGpreHAB feasibility study evaluates the feasibility of a home-based multimodal prehabilitation intervention for patients awaiting elective CABG surgery. This randomized pilot study compares the intervention plus usual care to usual care alone, assessing feasibility outcomes like recruitment, retention, attrition, fidelity, and adherence. The study aims to optimize a subsequent full-scale randomized controlled trial (RCT) and improve patient outcomes by leveraging the pre-surgery period for prehabilitation.

Eligibility Criteria

Inclusion Criteria: * Planned to have elective isolated first-time CABG surgery. * 18 years or older * Two weeks or more before surgery * Speaks and understands Danish. * Gives written informed consent. Exclusion Criteria: * Patient with unstable angina pectoris and/ or MI during the last two weeks. * Left main stem stenosis \>50% * Left ventricular ejection fraction \< 35% * Significant ventricular arrhythmia * Orthopedic or neurologic preconditions precluding exercise training. * Inability to attend the prehabilitation program due to physical limitations. * Patients who have cognitive deficits that would disqualify prehabilitation. * Severe heart failure, NYHA Class IV * Lack of capacity to consent

Contact & Investigator

Central Contact

Dorte Baek Olsen, PhD student

✉ dorte.baek.olsen@regionh.dk

📞 +4526625705

Principal Investigator

Ida E Hoejskov, PhD

PRINCIPAL INVESTIGATOR

Department of Heart Disease, Rigshospitalet, Copenhagen University Hospital

Frequently Asked Questions

Who can join the NCT07035171 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Ischaemic Heart Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07035171 currently recruiting?

Yes, NCT07035171 is actively recruiting participants. Contact the research team at dorte.baek.olsen@regionh.dk for enrollment information.

Where is the NCT07035171 trial being conducted?

This trial is being conducted at Copenhagen, Denmark.

Who is sponsoring the NCT07035171 clinical trial?

NCT07035171 is sponsored by Rigshospitalet, Denmark. The principal investigator is Ida E Hoejskov, PhD at Department of Heart Disease, Rigshospitalet, Copenhagen University Hospital. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology